Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
Independent Data Monitoring Committee recommends dose increase for 177Lu-SN201 in Tumorad-01 Phase I/IIa trial after reviewing safety data from six patients across five cancer types.
Spago Nanomedical announces strategic restructuring to focus resources on Tumorad program and ongoing phase I/IIa study, discontinuing internal preclinical discovery activities.
Spago Nanomedical focuses resources on its Tumorad program and the clinical development of 177Lu-SN201, a cancer-targeting drug.